TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19952403
Drug: Aminophylline (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (5 mg/kg) injected slowly via the vein after anesthesia and maintained at 0.5 mg/(kg.h) until the end of CPB
Study: 19952403
Drug: Ringer's lactated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's lactated solution (control group)
Study: 17264717
Drug: 8% sevoflurane
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8% sevoflurane in oxygen (8 l/min) via a prefilled circuit, end‐tidal sevoflurane maintained at 4%
Study: 28911070
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (IC) with docetaxel/cisplatin/5 fluorouracil (TPF) followed by CCRT (Arm B1)
Study: 28911070
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (IC) with docetaxel/cisplatin/5 fluorouracil (TPF) followed by CET/RT (Arm B2)
Study: 28911070
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (IC) with docetaxel/cisplatin/5 fluorouracil (TPF) followed by CCRT or CET/RT
Study: 28911070
Drug: Concomitant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant treatment alone with CCRT (Arm A1)
Study: 28911070
Drug: Concomitant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant treatment alone with CET/RT (Arm A2)
Study: 25580989
Drug: 0.38% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.38% ropivacaine continuous wound infusion (CWI) at 5 ml/h after laparotomy or 2 ml/h after laparoscopy
Study: 25580989
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline continuous wound infusion (CWI) at 5 ml/h after laparotomy or 2 ml/h after laparoscopy
Study: 21425884
Drug: Methylphenidate transdermal
Normalized name: methylphenidate Transdermal System
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate transdermal system 10-30 mg
Study: 12851662
Drug: Placebo transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo transdermal system
Study: 21425884
Drug: Methylphenidate transdermal
Normalized name: methylphenidate Transdermal System
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate transdermal system
Study: 18417466
Drug: Antipsychotic cotreatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic cotreatment
Study: 17055302
Drug: Thrombin-soaked gel
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombin-soaked gel foam
Study: 17055302
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution lavage with sponge drying
Study: 2010899
Drug: Three-day diet
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-day diet containing greater than 150 g/d of carbohydrate (group I)
Study: 2010899
Drug: Normal dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal dietary pattern without dietary preparation (group II)
Study: 3736281
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg diazepam
Study: 6121766
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg buspirone hydrochloride
Study: 6121766
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg buspirone hydrochloride
Study: 27422154
Drug: 0.3mg rhTSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3mg rhTSH stimulation before radioiodine therapy (group I)
Study: 25856740
Drug: Emotion-regulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emotion-regulation therapy combined with cognitive group therapy ('Before and beyond')
Study: 25856740
Drug: Normal individual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal individual treatment
Study: 21212432
Drug: Rituximab in
Normalized name: rituximab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab in combination with fludarabine and cyclophosphamide (FC)
Study: 11675939
Drug: Diuretic (trichlormethiazide)
Normalized name: Trichlormethiazide
DrugBank: Trichlormethiazide (DB01021)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diuretic (trichlormethiazide)
Study: 7701044
Drug: Cocaethylene (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaethylene (0.25 mg/kg cocaethylene base)
Study: 7701044
Drug: Cocaine (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine (0.25 mg/kg cocaine base)
Study: 22230406
Drug: Neo-adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neo-adjuvant chemotherapy with cisplatin and gemcitabine plus immunotherapy with PBMC and rIL-2
Study: 22230406
Drug: Neo-adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neo-adjuvant chemotherapy with cisplatin and gemcitabine
Study: 16924981
Drug: No-treatment (n=24)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment (n=24)
Study: 15689090
Drug: Two-dose varicella
Normalized name: VARICELLA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-dose varicella vaccine
Study: 15689090
Drug: One-dose varicella
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One-dose varicella vaccine
Study: 14622777
Drug: 4030W92 (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4030W92 (25 mg/day)
Study: 7624492
Drug: Levetiracetam (pyrrolidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam (pyrrolidine derivative) as an antiepileptic concomitant drug
Study: 140824
Drug: Ro 11-1430
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 11-1430 (0.1% lotion)
Study: 140824
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A acid (0.05% lotion)
Study: 140824
Drug: Placebo (lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (lotion alone)
Study: 31495658
Drug: Multimodality stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodality stimulation combined with standard physiotherapy (therapy group)
Study: 27794487
Drug: Direct skill
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct skill training (n=22, 10 sessions as adjunct to usual inpatient rehabilitation)
Study: 27794487
Drug: Guided training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided training (n=21, same dose)
Study: 12243915
Drug: Tamoxifen 20
Normalized name: tamoxifen 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 20 mg/day for 5 years
Study: 23335675
Drug: Raloxifene 60
Normalized name: raloxifene 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene 60 mg/day for 5 years
Study: 17314736
Drug: Raloxifene 60
Normalized name: raloxifene 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene 60 mg/day + 17beta‐estradiol 1 mg/day (RLX + E)
Study: 14752071
Drug: Oral fluoropyrimidines
Normalized name: 5-Fluoropyrimidine-2,4-dione
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral fluoropyrimidines for 1 year
Study: 11096006
Drug: Mupirocin treatment
Normalized name: Mupirocin
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mupirocin treatment
Study: 8956398
Drug: Subarachnoid neostigmine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subarachnoid neostigmine 75 micrograms (1.5 mL)
Study: 8956398
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received 1.5 mL subarachnoid saline
Study: 8956398
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received 15 mg (3 mL) of hyperbaric bupivacaine 0.5%
Study: 4055985
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg m‐CPP, orally
Study: 28851788
Drug: Regional transarterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regional transarterial hypothermic infusion (cold saline at 15°C) administered through a microcatheter in the ipsilateral internal carotid artery after thrombectomy when no improvement in NIHSS score is observed.
Study: 23588685
Drug: Strawberry-flavored lozenge
Normalized name: pectin
DrugBank: Pectin (DB11158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strawberry-flavored lozenge (Strepsils® strawberry sugar free)
Study: 23588685
Drug: Orange-flavored lozenge
Normalized name: polyethylene glycol 3350
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orange-flavored lozenge (Strepsils® orange with vitamin C)
Study: 14687901
Drug: Benzbromarone treatment
Normalized name: benzbromarone
DrugBank: Benzbromarone (DB12319)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzbromarone treatment
Study: 11518893
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 150 mg fluconazole
Study: 11518893
Drug: Two sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two sequential doses of 150 mg fluconazole given 3 days apart
Study: 11518893
Drug: Two-dose fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two-dose fluconazole regimen
Study: 11518893
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of fluconazole
Study: 8853725
Drug: Fluconazole therapy
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole therapy
Study: 3276469
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral and parenteral antimicrobial prophylaxis
Study: 3276469
Drug: Parenteral antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral antimicrobial prophylaxis
Study: 26412215
Drug: Mixed nuts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed nuts (30 g/d) for 12 weeks
Study: 16540953
Drug: Oxygen catheter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen catheter (6 L/min)
Study: 16540953
Drug: T-piece system
Normalized name: T-5224
DrugBank: T-5224 (DB05998)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-piece system (12 L/min)
Study: 16540953
Drug: CPAP system
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP system (10 cm H2O, 12 L/min)
Study: 12880400
Drug: Carbon fibre
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbon fibre reinforced carbon (CFRC) endodontic post cemented with a composite luting agent
Study: 11025363
Drug: THL 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: THL 120 mg t.i.d.
Study: 8881951
Drug: Finasteride treatment
Normalized name: Finasteride
DrugBank: Finasteride (DB01216)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Finasteride treatment for a minimum of 9 months
Study: 7646574
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg omeprazole daily
Study: 1411281
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg famotidine daily
Study: 30354562
Drug: DASH/SRD (Dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: DASH/SRD (Dietary Approaches to Stop Hypertension meals; 1500 mg sodium/d)
Study: 22678051
Drug: Caffeinated coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeinated coffee (237 ml, 182 mg caffeine)
Study: 22678051
Drug: Decaffeinated coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decaffeinated coffee (237 ml, 4 mg caffeine)
Study: 20546197
Drug: Modified sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified sequential three-step empirical therapy
Study: 20546197
Drug: Primary sequential
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary sequential three-step empirical therapy
Study: 15697327
Drug: Mirtazapine 15-60
Normalized name: mirtazapine 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine 15-60 mg/day (n = 147)
Study: 15697327
Drug: Fluoxetine 20-40
Normalized name: fluoxetine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20-40 mg/day (n = 152)
Study: 7805082
Drug: Warfarin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin and Aspirin combination
Study: 7805082
Drug: Low-dose Warfarin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Warfarin
Study: 2686257
Drug: ISDN/ISMN (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISDN/ISMN (120 mg/50 mg) + Diltiazem (D)
Study: 2686257
Drug: ISDN/ISMN (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISDN/ISMN (120 mg/50 mg)
Study: 2686257
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with Diltiazem (D)
Study: 27844472
Drug: Tapentadol PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapentadol PR (100-250 mg bid)
Study: 24985410
Drug: Oxycodone CR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone CR (20-50 mg bid)
Study: 24831754
Drug: Individual drug
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual drug counseling in addition to buprenorphine-naloxone and medical management
Study: 22540417
Drug: FertilMate™ Scrotum
Approvals — FDA: no, EMA: no, PMDA: no
Description: FertilMate™ Scrotum Cooling Patch for 90 days
Study: 22540417
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not wearing patches)
Study: 11421509
Drug: Formoterol added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol added to low dose budesonide
Study: 11421509
Drug: Formoterol added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol added to moderate doses of budesonide
Study: 7733470
Drug: Ketamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.5 to 0.75 mg/kg)
Study: 3349555
Drug: Edrophonium 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium 0.2 mg.kg‐1 (Group V)
Study: 2644050
Drug: Edrophonium 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium 0.15 mg.kg‐1 (Group IV)
Study: 2644050
Drug: Edrophonium 0.1
Normalized name: atropine-edrophonium 0.14 mg-10 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium 0.1 mg.kg‐1 (Group III)
Study: 2644050
Drug: Edrophonium 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium 0.05 mg.kg‐1 (Group II)
Study: 2644050
Drug: Edrophonium 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium 1.0 mg.kg‐1 (Group I, controls)
Study: 4911774
Drug: Vitamin B12
Normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B12 therapy
Study: 11485076
Drug: Phyllanthus amarus
Normalized name: Phyllanthus amarus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phyllanthus amarus compound (PA Co)
Study: 2292635
Drug: Monthly Assertion
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly Assertion Training Boosters (ATB)
Study: 2292635
Drug: Monthly Attention
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly Attention Placebo Boosters (APB)
Study: 6108780
Drug: Metoprolol (ME)
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol (ME) 75 mg to 242 mg
Study: 6108780
Drug: Pindolol (PI)
Normalized name: Pindolol
DrugBank: Pindolol (DB00960)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pindolol (PI) 7.5 mg to 23 mg
Study: 6108780
Drug: Propranolol (PR)
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propranolol (PR) 60 mg to 233 mg
Study: 31655603
Drug: CHO-HG (2.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO-HG (2.2 g CHO-HG·min-1)
Study: 31721447
Drug: Trastuzumab emtansine
Normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab emtansine 2.4 mg/kg weekly
Study: 24657236
Drug: Omalizumab 450
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Omalizumab 450 mg
Study: 24657236
Drug: Omalizumab 525
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Omalizumab 525 mg
Study: 24657236
Drug: Omalizumab (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omalizumab (all doses)
Study: 20668329
Drug: In house
Normalized name: NIACINAMIDE 2 g in 100 mL TOPICAL CREAM [THE SKIN HOUSE Vital BrightCream]
Approvals — FDA: no, EMA: no, PMDA: no
Description: In house autologous platelet gel
Study: 20668329
Drug: Vivostat‐ gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vivostat‐ gel
Study: 18970976
Drug: BG00012 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: BG00012 240 mg three times daily
Study: 15609386
Drug: Placebo and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and aspirin
Study: 9989124
Drug: Sertraline 50-100
Normalized name: sertraline 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 50-100 mg per day for 8 weeks
Study: 1462277
Drug: Tenormin (atenolol)
Normalized name: atenolol Oral Tablet [Tenormin]
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenormin (atenolol) 100 mg daily
Study: 3882061
Drug: Diltiazem 120
Normalized name: diltiazem 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 120 mg three times a day for two weeks
Study: 26561390
Drug: A/H5N1 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: A/H5N1 vaccine with AS03 adjuvant
Study: 25060370
Drug: Clopidogrel (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (both doses)
Study: 23249323
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of daytrip tickets and gift vouchers
Study: 15723869
Drug: Standard periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard periodontal therapy (SPT)
Study: 21757386
Drug: Intensive periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive periodontal therapy (IPT)
Study: 12049860
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg fondaparinux once daily
Study: 12049860
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg enoxaparin twice daily
Study: 9866433
Drug: Distant Healing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distant Healing (DH) treatment for 10 weeks
Study: 7839424
Drug: Cross-match study
Normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cross-match study (CS) patients with detectable lymphocytotoxic antibodies (LA)
Study: 2126584
Drug: High-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose aspirin (100 mg/kg/day)
Study: 2126584
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (30 mg/kg/day)
Study: 28206788
Drug: Expectations for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expectations for antibiotics (Experiment 1)
Study: 28206788
Drug: Expectations for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expectations for antibiotics (Experiment 2)
Study: 26323830
Drug: Value-based cognitive-behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Value-based cognitive-behavioural therapy (V-CBT) delivered within the first three months after a whiplash injury.
Study: 19857076
Drug: Daily consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily consumption of jelly containing 0.3 g of S. euboea extract
Study: 19857076
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (daily consumption of the same jelly without the enrichment)
Study: 17156591
Drug: 1-hour pamidronate
Normalized name: Pamidronate
DrugBank: Pamidronic acid (DB00282)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1-hour pamidronate infusion
Study: 17156591
Drug: 2-hour pamidronate
Normalized name: Pamidronate
DrugBank: Pamidronic acid (DB00282)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2-hour pamidronate infusion
Study: 11694775
Drug: Continuous 24-hour
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous 24-hour infusion of 5-fluorouracil (5-FU) 2,600 mg/m2 with folinic acid (FA) 500 mg/m2
Study: 9366934
Drug: Bupivacaine 0.5%
Normalized name: BUPivacaine 0.5% injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.5% (8.5 +/- 1.5 ml)
Study: 9366934
Drug: Placebo (8.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (8.3 +/- 1.8 ml)
Study: 8904618
Drug: Fluconazole 50
Normalized name: fluconazole 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 50 mg
Study: 3111360
Drug: Ceftazidime 50
Normalized name: ceftazidime 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 50 mg/kg per dose administered intravenously every 8 h for 14 days
Study: 3111360
Drug: Ceftazidime 75
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftazidime 75 mg/kg per dose administered intravenously every 8 h for 14 days
Study: 27733020
Drug: Topical oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical oxygen therapy
Study: 24729102
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of alpha lipoic acid (ALA) supplementation daily for 8 weeks
Study: 24729102
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules daily for 8 weeks
Study: 21106264
Drug: IV N-acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV N-acetylcysteine plus high-dose hydration with normal saline
Study: 21106264
Drug: High-dose hydration
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose hydration with normal saline
Study: 18680998
Drug: Various intensive
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various intensive therapy schemes
Study: 15768050
Drug: APC expression
Normalized name: APC-356433
Approvals — FDA: no, EMA: no, PMDA: no
Description: APC expression levels in leukocytes of relapse patients taking antipsychotic medication
Study: 15768050
Drug: APC expression
Normalized name: APC-356433
Approvals — FDA: no, EMA: no, PMDA: no
Description: APC expression levels in leukocytes of first-episode drug-naïve patients